Clinical Trial: Pembrolizumab and Pemetrexed for Progressive Chordoma

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794645) titled 'Pembrolizumab and Pemetrexed for Progressive Chordoma' on Nov. 21, 2024.

Brief Summary: Primary Objective:

1. To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression. The OOR will be investigator assessed.

Secondary Objectives:

1. To describe the adverse events associated with administering pembrolizumab and high-dose pemetrexed combination treatment.

2. To determine disease control rate based on imaging and overall survival.

3. To determine median PFS and PFS rates at 6, 9, 12, and 18 months.

4. To evalua...